Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended
Aug. 19, 2021
Aug. 09, 2021
Jul. 31, 2021
Jul. 31, 2020
Sep. 13, 2021
Apr. 30, 2021
Apr. 30, 2020
Indefinite-lived Intangible Assets [Line Items]              
Intangible assets     $ 3,549,427     $ 3,549,427  
Impairment of intangible assets     0 $ 0      
Research and development costs     143,613 270,574      
Uninsured cash balances     679,000     1,921,000  
Retained Earnings (Accumulated Deficit)     108,434,913     107,409,495  
Net Income (Loss) Attributable to Parent     1,025,418 883,944      
Cash     959,270 $ 2,166,596   $ 2,202,106 $ 894,861
Subsequent Event [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Proceeds from Issuance or Sale of Equity $ 70,000,000 $ 15,000,000          
Cash         $ 88,000,000    
Cell In A Box [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Intangible assets     1,549,427        
Diabetes License [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Intangible assets     $ 2,000,000        
S G Austria [Member]              
Indefinite-lived Intangible Assets [Line Items]              
Percentage investment in SG Austria     14.50%